
Outset Medical (OM) Stock Forecast & Price Target
Outset Medical (OM) Analyst Ratings
Bulls say
Outset Medical Inc. has demonstrated strong performance in console sales during Q3, surpassing expectations despite a significant order delay, which positions the company for improved profitability through ongoing cost reduction and efficiency initiatives. The company is also on track to meet its target of less than $50 million in cash burn for 2025, achieving approximately $6 million in cash burn for the quarter, which reflects a commitment to enhancing financial sustainability. Additionally, with an adjusted gross margin of 39.8%, exceeding both consensus forecasts and the company's own guidance, Outset Medical shows promising potential for expanding its market share in both acute and home hemodialysis settings.
Bears say
Outset Medical Inc. has experienced significant revenue setbacks, prompting a downward revision of its full-year guidance by approximately $7 million, influenced by delays in enterprise deal timing and a disappointing consumables performance. The company reported total revenues of $29.4 million, falling short of both expectations and consensus estimates, primarily due to softer than anticipated consumable sales and interruptions from a key leadership change in the sales department. With the outlook for 2026 remaining cautious and uncertainty surrounding future revenue streams, investor confidence is likely to be negatively impacted.
This aggregate rating is based on analysts' research of Outset Medical and is not a guaranteed prediction by Public.com or investment advice.
Outset Medical (OM) Analyst Forecast & Price Prediction
Start investing in Outset Medical (OM)
Order type
Buy in
Order amount
Est. shares
0 shares